Compare Crispr Therapeutics AG (CRSP) vs Gap Inc (GAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Gap Inc — how do they compare? Crispr Therapeutics AG trades at $50.71 (market cap $4.97B), while Gap Inc trades at $20.19 (market cap $7.25B). The key difference: Gap Inc is the larger of the two by market cap, and Gap Inc pays a 3.48% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | GAP | |
|---|---|---|
Market Cap | $4.97B | $7.25B |
Sector | Health | Consumer Cyclical |
52-Week High | $76.78 | $29.13 |
52-Week Low | $44.34 | $18.35 |
Enterprise Value | $3.32B | $10.33B |
Dividend Yield | — | 3.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Gap Inc. (GAP) trades at $19.80, up 1.75% today, with a bearish technical signal despite neutral oscillators. The stock shows strong fundamentals with a P/E of 7.86 and net income margin of 6.25%, supported by a 10-quarter positive comp trend. Recent news highlights a digital transformation with AI-led marketing and ongoing legal investigations.
The outlook is mixed; valuation metrics suggest upside to the $27 consensus target, but near-term risks include legal probes and Athleta's turnaround pace. Earnings growth and margin expansion remain key catalysts, though investor sentiment is cautious amid bearish technicals and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Gap Inc
Gap retails apparel, accessories, and personal-care products under the Gap, Old Navy, Banana Republic, and Athleta brands. Old Navy generates more than half of Gap's sales. The firm also operates e-commerce sites, outlet stores, and specialty stores under various Gap names. Gap operates nearly 3,000 stores in North America, Europe, and Asia and franchises about 600 stores in Asia, Europe, Latin America, and other regions. Gap was founded in 1969 and is based in San Francisco.
Read more on GAP →
